Correspondence 0001104659-24-092030 from SEELOS THERAPEUTICS, INC. (SEEL) (CIK 0001017491)
SEELOS THERAPEUTICS, INC. (SEEL) (CIK 0001017491)
Date: Aug. 22, 2024 · CIK: 0001017491 · Accession: 0001104659-24-092030
AI Filing Summary & Sentiment
File numbers found in text: 333-281604
Letter
Seelos Therapeutics, Inc.
300 Park Avenue, 2nd Floor
New York, NY 10022
August 22, 2024
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, D.C. 20549
Attn: Daniel Crawford
Re: Seelos Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 16, 2024
File No. 333-281604
Ladies and Gentlemen:
Seelos Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effectiveness of the above-referenced registration statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on August 23, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Company understands that the Commission will consider this request for acceleration of the effective date of the above-referenced registration statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the above-referenced registration statement.
Very truly yours,
Seelos Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Seelos Therapeutics, Inc.
300 Park Avenue, 2nd Floor
New York, NY 10022
August 22, 2024
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, D.C. 20549
Attn:
Daniel Crawford
Re:
Seelos Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 16, 2024
File No. 333-281604
Ladies and Gentlemen:
Seelos Therapeutics, Inc.
(the “Company”) hereby requests acceleration of the effectiveness of the above-referenced registration statement pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective
on August 23, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Company understands that
the Commission will consider this request for acceleration of the effective date of the above-referenced registration statement as a confirmation
of the fact that the Company is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended,
as they relate to the proposed public offering of the securities specified in the above-referenced registration statement.
Very truly yours,
Seelos Therapeutics, Inc.
By:
/s/ Michael Golembiewski
Michael Golembiewski
Chief Financial Officer
cc:
Ron Ben-Bassat, Esq.